Learn how AbbVie could help you save on SKYRIZI.
Call 1.866.SKYRIZI or click tap to learn more ▸
The amount you pay for SKYRIZI can depend on a number of factors, including your access to prescription drug coverage, the type of insurance you have, and even the level of coverage your insurance may provide.
This page provides information that can help you determine how much SKYRIZI may cost for you, as well as financial support programs that may be able to help you afford your medication.
The list price, also known as the Wholesale Acquisition Cost (WAC), for one dose of SKYRIZI, is $19,734.61 as of January 2023. The WAC may not reflect the price paid by patients.
Call 1.866.SKYRIZI (1.866.759.7494) to find out how much SKYRIZI will cost for you.
If you have:
You could pay:
Commercial Insurance (Usually provided by an employer)
$5 per dose,† 4 times a year, with the Skyrizi Complete Savings Card. Learn about the card.
Medicaid
$20.00 or less per dose, depending on state plan.
Medicare Part D
$987.00 - $3,530.00‡ per dose, depending on coverage phase.
‡Represents catastrophic phase SKYRIZI cost.
Out-of-pocket cost for SKYRIZI may vary depending on patient’s other medication costs.
Most Medicare patients have standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1.866.SKYRIZI (1.866.759.7494).
Medicare Low Income Subsidy (LIS)
$10.35 per dosing starting January 1, 2023.
Other Insurance
Because coverage varies by plan, call 1.866.SKYRIZI (1.866.759.7494) to speak to an Insurance Specialist to find out how much SKYRIZI will cost for you.
Uninsured or if you cannot afford your medication
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/
myAbbVieAssist to learn more.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.
The chart above provides cost information based on what a person with the type of coverage listed may pay for one (1) 150mg/mL dose of SKYRIZI, which is generally every 3 months. Your type of health or prescription insurance plan will determine exactly how much you will pay. Information listed is accurate as of January 2023 and is based on publicly available benefit design information for Medicaid and Medicare Part D out-of-pocket costs for 2023 plan year.
†Eligibility: Available to patients with commercial insurance coverage for SKYRIZI (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit SKYRIZISavingsCard.com or call 1.866.SKYRIZI for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie
To help you understand your coverage and what your out-of-pocket costs may be, it's important to verify your benefits.
And even if your SKYRIZI isn't covered, there may be ways to save on your prescription. An Insurance Specialist can talk you through your coverage and help identify potential savings options––regardless of your insurance coverage.
For insurance questions or to verify your benefits, call 1.866.SKYRIZI (1.866.759.7494)
With the Skyrizi Complete Savings Card, eligible commercially insured patients may pay as little as $5 per quarterly dose.‡
Find out how you can start saving today!
**For eligible, commercially insured patients. Please see Terms and Conditions here.
‡$5 per quarterly dose for SKYRIZI, and for each starting dose—Week 0 and Week 4.
If you are having difficulty paying for your medicine, myAbbVie Assist may be able to help.
myAbbVie Assist, our patient assistance program, provides AbbVie medicine to qualifying patients. It is intended for people that live in the United States, have limited or no health insurance coverage and demonstrate qualifying financial need.
Visit AbbVie.com/myAbbVieAssist to learn more.
SKYRIZI is a prescription medicine used to treat adults with:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems in Crohn's disease: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
SKYRIZI is a prescription medicine used to treat adults with:
US-SKZ-220579
Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.
Legal Notices/Privacy Policy. Copyright 2023, AbbVie Inc., North Chicago, Illinois, U.S.A. If you have any questions about AbbVie’s SKYRIZI.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
US-SKZ-220373
US-SKZ-220373
